AEON Biopharma, Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off
AEON Biopharma, Inc. (AEON) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $348.00 million for the 5-month period ending 2023-12-31, per its 10-K/A filed 2024-05-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2024-05-14
- 2023-12-31: Research and Development Asset Acquired Other than Through Business Combination, Written-off 5 month $348.00M.
- 2023-07-21: Research and Development Asset Acquired Other than Through Business Combination, Written-off $348.00M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off | Research and Development Asset Acquired Other than Through Business Combination, Written-off 5 month |
|---|---|---|
| 2023-12-31 | $348.00M 10-K/A · filed 2024-05-14 | |
| 2023-07-21 | $348.00M 10-K/A · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |